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Original Research
Introduction
In 2018, some 1,735,350 people in the United States will be 
diagnosed with cancer (American Cancer Society, 2018). 
The emotional stress of receiving a cancer diagnosis is a dev-
astating setback. Physical and psychological impairments 
associated with the discovery of cancer may lead to an inabil-
ity to carry out normal, everyday activities for any person. 
More specifically, female patients under the age of 45 who 
are diagnosed with cancer may experience increased psycho-
social distress attributed to the feeling of having much life 
left to live and many responsibilities to maintain. Women 
under 45 are most commonly diagnosed with breast, colorec-
tal, and lung cancers (American Cancer Society, 2018). As 
many as one in 19 women in the United States will be diag-
nosed with some form of cancer before the age of 45 
(American Cancer Society, 2018).
Fortunately, in the past 20 years, cancer detection and 
early prevention measures have improved significantly. 
Providers now employ cancer genetic testing (CGT) for early 
identification of hereditary cancer syndromes, allowing for 
earlier identification and prevention of cancer (Baylin & 
Jones, 2012; Matloff, Bonadies, Moyer, & Brierley, 2014). 
More than 200 hereditary cancer syndromes have been iden-
tified in cancer research. These syndromes account for 5% to 
10% of all cancer, with breast, colon, and/or endocrine neo-
plasia being the most highly penetrant. A susceptibility to 
inherited cancer is suspected with characteristics such as a 
diagnosis of the same type of cancer in two or more relatives 
on the same side of the family, more than one generation 
affected, and/or early age of diagnosis (Nagy, Sweet, & Eng, 
2004).
Still, the presence of a cancer-predisposing mutation in a 
family does not guarantee cancer development. Other factors 
such as patterns of inheritance determine cancer develop-
ment. Autosomal dominant inheritance causes a single 
altered copy of a gene to increase a person’s likelihood of 
cancer development. In this case, the person’s parent may 
also present effects of the mutation. Autosomal recessive 
inheritance gives a person an increased risk of cancer only if 
they inherit a mutated copy of the gene from both parents. 
Finally, X-linked recessive inheritance occurs when a female 
with a recessive cancer-predisposing mutation on one of her 
X chromosomes passes a copy of the gene to her son, who 
will then only have a copy of the altered chromosome and a 
resulting increased risk of cancer (National Cancer Institute, 
2016). With increases in knowledge of hereditary cancer 
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syndromes, CGT has become a standard of care in oncology 
and, increasingly, primary care settings.
The Role of CGT
CGT is a powerful means to discover deleterious mutations 
in a patient’s genes. In its simplest form, this technology 
allows for patients to know whether they are at increased risk 
of cancer beyond general population risk. It also allows indi-
viduals to make informed choices about cancer risk reduc-
tion, and if cancer is diagnosed, that it is done so at earlier 
stages (National Cancer Institute, 2016).
The primary reason people choose to undergo CGT is 
because of personal and/or positive family history of cancer 
(Burt & Neklason, 2005; Facing Our Risk of Cancer 
Empowered [FORCE], 2016; Gomy & Estevez Diz, 2013). A 
family history of a blood relative with a known mutation in a 
gene that increases cancer risk, a blood relative with two or 
more primary breast cancers, two or more relatives with 
breast cancer on the same side of the family with at least one 
diagnosed before age 50, or a blood relative with ovarian 
cancer are among various risk factors that increase a person’s 
likelihood of having a mutation themselves (FORCE, 2016). 
In addition, anyone with a personal or family history of three 
or more cancers such as pancreatic, prostate, melanoma, sar-
coma, adrenal, brain, leukemia, uterine, or other cancers also 
maintain a higher risk of deleterious mutation themselves 
(FORCE, 2016; Stoffel & Chittenden, 2010) Other reasons 
for undergoing CGT include having a family member or 
members who have had cancer at a younger age than normal 
(50 years or younger) or a family history of a known genetic 
mutation (Burt & Neklason, 2005; FORCE, 2016; Stoffel & 
Chittenden, 2010). Ethnicity is another determining factor in 
choosing to partake in genetic testing as well as any physical 
evidence that may be linked to an inherited cancer. For 
example, individuals who are Eastern European Jewish have 
a higher risk of carrying specific mutations in BRCA1 and 
BRCA2 genes (American Cancer Society, 2018).
The approach to genetic testing is analogous for all hered-
itary cancer syndromes (Burt & Neklason, 2005). A detailed 
review of the patient’s family history is first obtained to iden-
tify any probable genetic mutations (Burt & Neklason, 2005; 
National Cancer Institute, 2016).
Patients then attend genetic counseling, where informed 
consent for testing for a genetic mutation is obtained 
(American Academy of Pediatrics Committee on Bioethics, 
2001; Gomy & Estevez Diz, 2013).
A Brief History of Genetic Testing
The study of genetics began in 1865 when Gregor Mendel 
introduced the fundamental laws of inheritance (Mendel, 
1865). Mendel’s contributions along with significant 
advances in technology in the 20th century led to events such 
as the proposition of a relationship between chromosomes 
and cancer by Theodor Boveri, a description of the double 
helix structure of DNA by James Watson and Francis Crick, 
and the innovation of the Sanger sequencing method by 
Frederick Sanger (Boveri, 1929; Sanger, Nicklen, & Coulson, 
1977; Watson & Crick, 1953). These discoveries allowed 
scientists to develop genetic tests for conditions such as 
Down syndrome, cystic fibrosis, and muscular dystrophy 
(National Institutes of Health, 2010). By 1990, the Human 
Genome Project was launched to reveal a complete map of 
the human genome (Durmaz et al., 2015). The first report of 
the Human Genome Project claimed that the human body 
had 30,000 to 50,000 genes (Durmaz et al., 2015). The final 
report of the Human Genome Project in 2003 revealed 93% 
of the human genome and declared that the human genome 
contained 20,000 to 25,000 protein-coding genes (Durmaz 
et al., 2015). During the late 1990s, the study of genetics 
focused on the central role of epigenetic processes regarding 
disease causation (Baylin & Jones, 2012). Before long, 
genetic testing became a standard procedure for clinical indi-
cations such as screening newborns for health conditions 
(National Institutes of Health, 2010). In 1996, BRCA1 and 
BRCA2 were cloned, shifting the focus of genetic testing to 
cancer (Matloff et al., 2014).
In the past 10 years, CGT has evolved from a rare, costly 
subspecialty to a practice that is a standard of care in the 
cancer management continuum (Baylin & Jones, 2012; 
Matloff et al., 2014). Recent gene sequencing techniques 
have revolutionized the ability of scientists to recognize 
nucleosome positioning and how changes in these contribute 
to cancer (Kouzarides, 2007; Matloff et al., 2014). CGT is 
used today to confirm hereditary cancer syndrome diagnoses 
and serves as a path toward cancer prevention and early 
treatment (Burt & Neklason, 2005).
Genetic panel testing is a widely used measure of modern 
CGT. More specifically, genetic cancer panel testing is a pro-
cess used to examine several different cancers and risk vari-
ants simultaneously (Hiraki, Rinella, Schnabel, Oratz, & 
Ostrer, 2014; Meldrum, Doyle, & Tothill, 2011; Santos et al., 
2012). Because of their cost-effectiveness, panel tests permit 
scientists to sequence multiple targets associated with cancer 
risk (Hiraki et al., 2014). In addition, panel testing allows for 
the testing of large amounts of gene targets to clearly under-
stand a patient’s risks (Hiraki et al., 2014). Panel testing 
yields various results that are explained to patients during 
genetic counseling: positive, negative, true negative, unin-
formative negative, false negative, variant of unknown sig-
nificance, and benign polymorphism (National Cancer 
Institute, 2016).
Gene expression signatures are another up-and-coming 
tool used to reveal clinically significant characteristics of 
biological samples. These signatures are used to recognize 
not only mutations in single genes but also distinct subtypes 
of tumors. Gene signatures can identify cellular responses to 
their environment and predict cancer outcomes, aiding in 
cancer monitoring and treatment (Chang et al., 2011). A 
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study conducted by the Champalimaud Clinical Center in 
Lisbon, Portugal, examined MammaPrint, a 70-gene signa-
ture test, to determine its ability to predict clinical outcomes 
for patients with early-stage breast cancer. This study exam-
ined 6,693 women with early-stage breast cancer and, using 
the 70-gene signature test, determined their genomic risk. 
Clinical risk was also identified using a modified version of 
Adjuvant! Online. Women with a high clinical risk and low 
gene signature risk who were not treated with chemotherapy 
were found to have a 5-year rate of survival without metasta-
sis, only 1.5 percentage points lower than those women who 
did receive chemotherapy. The study concluded that some 
46% of women with breast cancer and a high clinical risk 
may not require chemotherapy (Cardoso et al., 2016). The 
use of gene signatures alongside panel testing provides a 
broadened view of a patient’s cancer recurrence risk to best 
construct their treatment plan.
Despite great advances in CGT, no test has perfect predict-
ability. The quality of cancer genetic tests is described by how 
well the test determines who truly has the disease (sensitivity) 
and by how well the test tells who does not have the disease 
(specificity). A very sensitive test will detect even the slight-
est abnormal finding. Highly sensitive tests may leave cases 
of cancer undetected, but may also result in false-positive 
results. A test with high specificity will have fewer false-pos-
itive results, but will have more false negatives (Susan G. 
Komen Foundation, 2018).
Currently, research is being carried out to identify stron-
ger avenues of detecting and treating cancer among those 
who are found to carry deleterious genetic mutations. In the 
future, CGT and panel testing will continue to hold a crucial 
role in cancer care. It is expected that the cost of genetic test-
ing will continue to decline such that, eventually, a person’s 
entire genome will cost less than US$1,000 to sequence 
(National Institutes of Health, 2010).
The Nurse’s Role in Genetic Testing
At the forefront of holistic patient care, nurses’ responsibility 
in CGT is becoming increasingly important. Nurses play a 
crucial role in genetic-based practice and take on numerous 
tasks such as gathering family history, assisting with 
informed decision making, and providing genetic counseling 
(Badzek, Calzone, Jenkins, Culp, & Bonham, 2013; Lea, 
2008; Pasche & Absher, 2011). While there are specific cre-
dentials required to be an advanced practice nurse in genet-
ics, Bachelor of Science in Nursing (BSN) programs across 
the United States are in the process of revision to incorporate 
essentials of the study of genetics into the curriculum 
(Phillips, 2006). Overall, however, genetics is becoming less 
of a specialty discipline and more of a standard factor in 
everyday holistic nursing care (Umberger, Holston, Hutson, 
& Pierce, 2013).
Very early in the CGT process, oncology nurses are 
responsible for gathering patients’ cancer family history. 
During this time, nurses serve as an educator for patients, 
teaching them about the importance of reviewing family his-
tory information when considering genetic testing (Lea, 
2008). Nurses also construct pedigrees from family histories 
to assess hereditary and nonhereditary disease risk factors 
(Phillips, 2006). Finally, nurses are responsible for identify-
ing potential genetic conditions or predisposition to disease 
based on family history (Phillips, 2006).
Another important role of many oncology nurses is assist-
ing with the informed patient decision-making process. After 
a patient’s family history is assessed and discussed, it is cru-
cial that patients be informed of the risks and benefits of 
CGT, the possible outcomes of testing, and choice about 
deciding to undergo testing (American Academy of Pediatrics 
Committee on Bioethics, 2001; Lea, 2008). Nurses are 
involved in all of these steps (Lea, 2008).
Advanced Practice Nurses in Genetics (APNGs) are spe-
cifically trained in the care of patients with genetic illnesses. 
These advanced practice nurses assist patients and families 
by assessing hereditary factors related to genetic conditions 
such as cancer. They also serve as a liaison between patient 
and physician for patient care management. APNGs acquire 
their positions by first earning a BSN degree and then attain-
ing a Master of Science in nursing in which they gain spe-
cialized clinical training in genetics (American Nurses 
Credentialing Center [ANCC], 2016).
Genetic counseling is often facilitated by advanced prac-
tice nurses before and after CGT to translate genetic infor-
mation to patients (Lea, 2008). Genetic counselors educate 
patients on hereditary cancer syndromes as well as the over-
all CGT process and its outcomes. Patients are informed of 
cancer prevention and management techniques, and avail-
able research on their cancer and are provided with resources 
to aid them in their journey (National Cancer Institute, 2016). 
Genetic counselors also educate patients on the physical and 
psychological risks of learning their genetic test results, 
along with the possibility of an uninformative result (National 
Cancer Institute, 2016). Genetic counselors typically first 
earn a bachelor’s degree in biology, social science, or nurs-
ing and later go on to participate in a master’s program 
accredited by the American Board of Genetic Counseling 
(National Society of Genetic Counselors [NSGC], 2016).
Historically, registered nurses have left much of genetic 
practice to advanced practice nurses. Baccalaureate pro-
grams in nursing, however, are constantly undergoing revi-
sions to incorporate further training in genetics into the 
curriculum. Currently, required genomic-related competen-
cies for registered nurses are separated into four categories: 
nursing assessment, identification, referral activities, and 
provision of education, care, and support (Phillips, 2006; 
Umberger et al., 2013). BSN programs educate students to 
consider genetic influences when considering appropriate 
interventions and to evaluate the impact of treatments on 
patient outcomes (Lea, 2008). Registered nurses are also 
responsible for the facilitation of referrals for specialized 
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genetic services for patients as needed. Unfortunately, chal-
lenges such as a lack of appreciation for the significance of 
genetics in nursing practice, faculty unpreparedness, and a 
lack of emphasis of genetics in RN licensure examinations 
hinder the progress of genetics in nursing education 
(Umberger et al., 2013). As CGT becomes more advanced, 
nurses will be increasingly responsible for communicating 
genetic information as an everyday part of cancer patient 
care.
Psychosocial Implications of CGT
With constant improvements in technology and medicine for 
oncology and genetics, participating in genetic testing will 
become more and more commonplace for standard cancer 
prevention and treatment. As the number of patients who 
undergo CGT increases, so increases the necessity of under-
standing CGT. Specifically, it is important to further examine 
the psychosocial impacts the results of genetic testing have 
on patients (Patenaude & Julian-Reynier, 2008). Numerous 
studies have been conducted to assess different aspects of 
these psychosocial implications among different groups of 
people.
Potential Psychosocial Concerns Associated With 
CGT
Several authors have found that genetic testing leads to nota-
ble psychosocial implications. In fact, it has been suggested 
that approximately one quarter of those who undergo CGT 
acquire some level of distress, anxiety, or depression 
(Pasacreta, 2003). One study conducted by the Swansea 
University (n = 194) found that up to three quarters of those 
who participated in their study reported concerns related to 
their experience with testing (Bennett et al., 2012). Of these 
concerns, over two thirds of participants reported apprehen-
sion and concern about how their families would react to 
their results, implications for family members of an increased 
risk result, and how participants would personally cope with 
an increased risk result. Other responses included concerns 
regarding the decision-making process based on testing 
results and the overall impact of genetic risk of cancer on 
lifestyle (Bennett et al., 2012).
Along these lines, another study conducted by the 
Netherlands Cancer Institute (n = 127) sought to identify 
specific psychosocial concerns related to genetic testing 
and counseling and to create a questionnaire designed to 
recognize these problems in individuals undergoing 
genetic testing in the oncology setting (Eijzenga et al., 
2014). The survey developed in the study, the Psychosocial 
Aspects of Hereditary Cancer (PAHC) questionnaire, con-
tained 26 questions organized into six major categories of 
identified problems: genetics, practical issues, family, liv-
ing with cancer, emotions, and children (Eijzenga et al., 
2014). The study concluded that when used in conjunction 
with the Distress Thermometer—a visual analog scale 
ranging from 0 to 10 to describe one’s distress—the PAHC 
questionnaire was an effective first-line screener for psy-
chosocial problems in candidates for genetic testing. Using 
these measures, the study found need for increased psy-
chosocial counseling after testing (Eijzenga et al., 2014; 
Tuinman, Gazendam-Donofrio, & Hoekstra-Weebers, 
2008).
While the studies above demonstrate noteworthy results 
regarding concerns associated with CGT, several of them 
possess important weaknesses as well. A few studies had 
small or unrepresentative samples (Pasacreta, 2003). Other 
studies were not performed in the United States (Bennett 
et al., 2012; Eijzenga et al., 2014; Tuinman et al., 2008). 
Furthermore, a few of the studies were carried out qualita-
tively, which may provide less insight into statistical evi-
dence (Bennett et al., 2012; Eijzenga et al., 2014).
Predictors of Potential Psychosocial Concerns 
Associated With CGT
Various factors have been attributed to a greater likelihood of 
acquiring psychosocial problems for patients who participate 
in CGT. According to one study in the Netherlands (n = 165), 
researchers searched for prognostic factors to predict which 
counselees were most likely to develop psychological prob-
lems after genetic testing (Voorwinden & Jaspers, 2016). 
Male and female participants above the age of 18 with a 50% 
or greater risk of BRCA1/2 or Lynch syndrome were surveyed 
at three different points to determine factors contributing to 
their emotional distress after testing (Voorwinden & Jaspers, 
2016). Overall, authors concluded that worries regarding can-
cer after genetic testing were best predicted by preexisting 
cancer worries, a positive deleterious result, a high-risk per-
ception of getting cancer, and being single (Voorwinden & 
Jaspers, 2016).
Hirschberg, Chan-Smutko, and Pirl (2015) also cited 
numerous existential risk factors that contribute to stress and 
anxiety regarding CGT. For example, a history of depres-
sion, use of medication, and high levels of distress at the time 
of testing resulted in greater levels of distress after genetic 
testing (Hirschberg et al., 2015). Whether or not a person had 
lost a family member to a hereditary cancer, especially if an 
individual lost a parent before the age of 13, was another 
strong indicator of potential distress. Coping styles and 
familial relationships also affected how a person handled the 
stress of results from genetic testing. Those with positive 
family relationships were more likely to adhere to counsel-
ing recommendations and displayed fewer symptoms of dis-
tress (Hirschberg et al., 2015). Finally, perceived risk and 
distress at baseline played a large role in predicting stress, 
especially in patients who overestimated their level of risk 
(Hirschberg et al., 2015).
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A study conducted in Hong Kong, China (n =76) sought 
to investigate the factors that predict psychological resilience 
in adults undergoing genetic testing for hereditary colorectal 
cancer. Researchers used a longitudinal design to test partici-
pants on four different occasions throughout 1 year (Ho, Ho, 
Bonanno, Chu, & Chan, 2010). This study concluded that 
baseline hope was a significant predictor of resilience for 
those participating in genetic testing and suggested further 
interventions to increase hope levels in patients to ease 
potential psychosocial harm caused by genetic testing (Ho 
et al., 2010).
Of the studies mentioned above, the most significant limi-
tation is that much of the literature surrounding risk factors 
for psychosocial distress associated with CGT is from other 
countries (Bennett et al., 2012; Ho et al., 2010). Further 
research in the United States may be necessary to determine 
the significance of these findings related to the American 
culture.
Potential Psychosocial Benefits Associated With 
CGT
Many investigators have found that while psychosocial 
implications may accompany CGT, symptoms such as 
depression and anxiety are no higher in patients who undergo 
testing than those who do not. A study conducted in 2011 was 
designed to determine impacts of genetic testing on the psy-
chological distress and cancer worry caused by genetic test-
ing, as well as perceived advantages of testing claimed by 
pancreatic cancer and melanoma patients (n = 60; Aspinwall, 
Taber, Leaf, Kohlmann, & Leachman, 2013). Results showed 
that participants who underwent genetic testing demon-
strated decreases in anxiety, depression, and cancer worry 
long term due to the knowledge of their test results (Aspinwall 
et al., 2011). One participant noted feeling “more at ease for 
[his or her] children’s sake” and that genetic testing granted 
“choices and options for the better about taking steps to pre-
vent” cancer (Aspinwall et al., 2011, p. 284). Other perceived 
benefits of genetic testing claimed by participants included 
the informational benefit of increased knowledge about mel-
anoma risk and its management, as well as the benefit of 
improved health behaviors and likelihood to increase prac-
tice of genetic screening (Aspinwall et al., 2011).
Another study that focused on patients undergoing genetic 
testing for Lynch syndrome revealed that positive genetic 
test results often lead to transient psychosocial repercus-
sions. However, patients appeared to have no long-term 
genetic testing–related depression or anxiety (Galiatsatos, 
Rothenmund, Aubin, & Foulkes, 2015). In fact, most signs of 
depression and anxiety related to genetic testing were seem-
ingly normal by 6 to 12 months (Galiatsatos et al., 2015).
According to the previously mentioned study by Ho et al. 
(2010), hereditary colorectal cancer patients who partici-
pated in this study exhibited little to no signs of depression or 
anxiety the year after disclosure of their genetic test results 
(Ho et al., 2010). It was concluded that a majority of those 
tested for hereditary colorectal cancer were psychologically 
resilient and exhibited little to no signs of depression imme-
diately after genetic testing (Ho et al., 2010). In fact, only 
8.7% of participants exhibited elevated symptoms of anxiety 
and another 7.2% symptoms of depression caused by genetic 
testing. Furthermore, it was estimated based on the results of 
the study that the percentage of participants exhibiting test-
related anxiety and depression would decrease to 7% to 9% 
by 12 months (Ho et al., 2010).
Voorwinden and Jaspers (2016) found that immediately 
after genetic testing, counselees with an unfavorable result 
demonstrated no more emotional distress than those with a 
favorable result. It was not until 4 to 6 weeks after testing 
those counselees with an unfavorable result demonstrated 
increased levels of stress and concern regarding their genetic 
testing results (Voorwinden & Jaspers, 2016).
Finally, a study measuring qualitative and quantitative 
outcomes of females with breast cancer found genetic testing 
to be psychologically advantageous to patients (Schlich-
Bakker, ten Kroode, & Ausems, 2006). The investigators 
concluded that females who participated in genetic testing 
and genetic counseling experienced reductions in anxiety, 
especially when counseling was tailored to their specific 
needs (Schlich-Bakker et al., 2006).
Limitations surrounding the studies regarding psychoso-
cial benefits associated with CGT include small sample size 
(Aspinwall et al., 2011) and the lack of exploration regarding 
various dynamics between nonmutation carriers such as 
affected family member reactions, coping mechanisms of 
partners of patients affected by a mutation, the impact of a 
diagnosis on career, and professional goals. In addition, fur-
ther research is necessary on the psychosocial aspects of 
patients who decline CGT (Galiatsatos et al., 2015).
Ethical Implications of CGT
With constant advances in technology, CGT continues to 
become less expensive and more affordable for many patients 
at risk of cancer. Panel testing, in particular, is a widely used 
tool for assessing genetic risk of multiple types of cancer. 
Panel testing is a popular form of personalized medicine that 
gives patients an objective response to understand their level 
of risk for cancer (Hiraki et al., 2014). Despite its benefits, 
however, panel testing presents various ethical dilemmas 
that must be taken into consideration (Hanoch, Miron-Shatz, 
Rolinson, & Ozanne, 2014; Hermel, McKinnon, Wood, & 
Greenblatt, 2016; Hiraki et al., 2014; Ormond et al., 2010; 
Surbone, 2001; Tabor et al., 2012; Tavtigian, Greenblatt, 
Goldgar, & Boffetta, 2008).
Defining the target population for panel testing is one 
challenge of using this approach. First, few people who wish 
to undergo genetic testing even meet the criteria to warrant 
testing of their specific cancer risk (Hiraki et al., 2014). For 
example, the first step in CGT is assessing the family history 
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(Gomy & Estevez Diz, 2013). Without a family history of 
hereditary cancer, many people are ineligible for panel test-
ing altogether, although they may still have concealed risk-
increasing mutations that would be uncovered from genetic 
testing (Hiraki et al., 2014). Furthermore, it is difficult to 
determine who has the right to the information of an indi-
vidual’s panel testing results. Antonella Surbone of Sloan 
Kettering Cancer Center in New York (2001) asks, “Does the 
daughter of a cancer patient have the right to know her moth-
er’s BRCA status?” (p. 153). There is great ethical dilemma 
between the determination of who has the right to know the 
results of an individual’s genetic testing and the importance 
of maintaining an individual’s confidentiality (Surbone, 
2001).
Another challenge in panel testing lies within the issue of 
informed consent. Informed consent requires that a patient 
be presented with adequate information so that they are fully 
aware of potential risks and benefits of a treatment before 
agreeing to proceed (Ormond et al., 2010). Unfortunately, 
providing a patient with all the details of potential strengths 
and limitations of panel testing may lead to information 
overload, inhibiting a patient’s proper decision-making abil-
ity (Hiraki et al., 2014). One study aimed to qualitatively 
gain understanding about patient expectations and percep-
tions regarding the potential risks and benefits of genetic 
testing (Tabor et al., 2012). This study found that traditional 
approaches to informed consent were not appropriate for 
genome sequencing and that these approaches often lead to 
excessive burden on participants. Increased knowledge of 
genetic risk can be life-altering, and obtaining ethical 
informed consent for panel testing is an area of controversy 
(Ormond et al., 2010).
Along these lines, genetic testing for children and adoles-
cents presents another ethical dilemma. A study by Botkin 
et al. (2015) reviewed the ethical, legal, and social implica-
tions of genetic testing in children. There are various herita-
ble conditions for which genetic testing provides highly 
predictive information about a patient’s future health status. 
When it comes to children, this information leads to con-
cerns regarding stigma and discrimination against children in 
some circumstances (Botkin et al., 2015). Furthermore, chil-
dren lack decision-making skills and are unable to give 
informed consent for themselves. Parents usually provide 
surrogate consent for their children with the child’s “best 
interest” at heart, a highly contentious concept in itself. 
While parents are generally the best-fitted surrogate consent-
givers for their children, defining a child’s “best interest” is 
multifaceted, and there are often cases when parents make 
decisions that seem opposite of the best interest of their child 
(Botkin et al., 2015). The ethical implications surrounding 
the genetic testing of children necessitate further 
investigation.
Perhaps the most significant challenge regarding cancer 
panel testing is the difficulty surrounding interpretation and 
communication of risk results between medical personnel 
and patients. Panel testing yields various results: a positive 
result means that a known pathogenic mutation is detected, 
a negative result means that no genetic variant is detected, 
and an ambiguous result means that a variant of uncertain 
significance (VUS) or benign polymorphism is detected 
(Hiraki et al., 2014; Tavtigian et al., 2008). While both pos-
itive and negative results generally lead to relatively con-
cise clinical decision making, an ambiguous result makes 
things much more complicated. According to Tavtigian 
et al. (2008), panel testing often finds “missense substitu-
tions, potential splicing variants, or small in-frame inser-
tion-deletions that are of uncertain significance” (p. 1261). 
In addition, testing for multiple gene mutations at a time 
increases the likelihood of producing a false-positive result 
or of detecting a VUS. The problem with an ambiguous 
VUS result is that there is little information regarding the 
effect of these less common genetic variants (Hiraki et al., 
2014; Walsh et al., 2010). As a result, the data to provide 
accurate genetic assessments are limited, making it difficult 
to interpret risk and challenging to present risks to patients 
(Hiraki et al., 2014). A study conducted by a Familial 
Cancer Program in Vermont (n = 277) reviewed factors that 
were potential predictors of variants of uncertain signifi-
cance and assessed changes in management tactics based 
on these factors (Hermel et al., 2016). Out of 227 patients, 
67 patients had genetic variants and eight patients had mul-
tiple variants. Forty-four patients in the study had a VUS. 
The study found that there were no single factors such as 
age or personal neoplasm history that could predict variants 
during panel testing. Only two cases where a VUS was 
identified resulted in the alteration of the patients’ manage-
ment tactics. Overall, it was noted that little could be done 
about ambiguous results with today’s technology (Hermel 
et al., 2016). The knowledge of the potential likelihood of 
uncovering a genetic mutation without a means to under-
stand or prevent the mutation is an ethical quandary that 
must be taken into consideration. Furthermore, when con-
ducting a panel test that searches for multiple mutations, it 
is possible to discover that a patient may carry multiple 
mutations or variants in multiple genes (Hiraki et al., 2014). 
Exposing new cancer risks in addition to the risks the panel 
test was looking for to begin with may be an unforeseen 
disadvantage of panel testing that must be thoroughly dis-
cussed with patients. Discovering the risk of having passed 
genetic mutations onto one’s child is an example of an 
unanticipated implication of panel testing that is considered 
ethically unsound (Rahman & Scott, 2007).
In addition to clinical uncertainty of results, patients 
often struggle to understand the meaning of testing results. 
A study conducted by the University of Plymouth in the 
United Kingdom recruited 477 women at risk of breast and 
ovarian cancer and asked them to interpret positive, true-
negative, ambiguous, and uninformative-negative results 
(Hanoch et al., 2014). While women were able to correctly 
interpret positive and negative results, they struggled to 
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understand the meaning of both uninformative and ambig-
uous results. When presented with uninformative-negative 
results, approximately half of the women learned nothing 
from the results. A substantial amount of women believed 
an uninformative-negative result signified a mere average 
probability of developing cancer. Other women believed 
an uninformed-negative result signified a decrease in can-
cer development risk. Ambiguous results yielded similar 
uncertainty in women’s interpretations. Over half of the 
sample viewed the ambiguous results as uninformative, 
40% saw ambiguity as an average risk of cancer, and a 
minority of women believed that ambiguity increased the 
risk of developing cancer (Hanoch et al., 2014). From 
these results, the study concluded that health care profes-
sionals should increase measures to ensure correct inter-
pretation of uninformative-negative and ambiguous results 
for patients (Hanoch et al., 2014). However, with little 
ability to treat variants of uncertain significance, it is dif-
ficult for medical professionals to fully communicate risks 
to patients. A VUS or benign result is clinically interpreted 
as a negative risk, but this is not how patients interpret the 
result.
Beyond issues with interpreting CGT results, recent 
studies suggest that people who learn their genetic risk of 
certain cancers often do not even take any actions with their 
results (Rapaport, 2016). A study conducted in California 
analyzed survey data from 762 customers who used direct-
to-consumer cancer-risk profiles to assess their cancer 
genetic risk. After 6 months, the study found that people 
who were at a higher risk of developing neoplasms were no 
more likely than those with an average risk to change their 
diet, exercise, or to seek cancer screening. The study con-
cluded that personalized CGT will not hold any “medical 
crystal ball” and that they alone will not even necessarily 
encourage patients to take action based on their results 
(Rapaport, 2016).
Risk management recommendations for VUS results are 
based on genetic and familial risk. Myriad Genetics, a molec-
ular diagnostic company, recommends that clinical manage-
ment of VUS carriers be based upon personal and family 
history and not the presence or absence of the variant itself. 
Each report given to patients after testing includes “guide-
line-based medical management considerations for negative 
and positive patients (either of which may contain variants of 
uncertain significance), and information for family mem-
bers” (Myriad Genetics Laboratories, 2018). Some health 
care providers choose to increase surveillance or pursue 
treatment options beyond that recommended for such vari-
ants (Plon et al., 2011). Still, there is no explicitly defined 
follow-up plan for VUS results. The unclear course of treat-
ment to pursue after receiving a VUS result may bring feel-
ings of increased anxiety for patients who undergo CGT. 
Challenges such as this surrounding the communication and 
interpretation of cancer panel testing present the potential for 
ethical turmoil.
Limitations in the Literature
Limitations in the extant literature on CGT are varied. 
Further research is needed regarding the psychosocial impli-
cations of CGT as a whole. It is becoming increasingly 
important to understand the impact of providing personal-
ized risk assessments via panel testing to implement a genetic 
testing process that enhances both the experience of patients 
and the clinical utility of the testing (Hiraki et al., 2014). In 
addition, the growing interest in CGT may require standard-
ized tools to fully understand and generalize the cognitive 
aspects of patients who undergo testing (Schlich-Bakker 
et al., 2006).
Many studies regarding the psychosocial implications of 
CGT provided the mean age of those who participated in the 
study. Most of the participants, both male and female, were 
from a wide age range, averaging around 47. This points to 
the importance of focusing on the influence of an individu-
al’s stage in life to understand the emotional impact of 
genetic testing and a potential cancer diagnosis (Schlich-
Bakker et al., 2006). More specifically, studying women 
under the age of 45 may present different psychosocial 
implications because these women potentially have young 
children, extensive responsibilities, and the expectation for a 
long life (Claes et al., 2004).
In addition to focusing on young females who undergo 
genetic testing, more research is needed on those who receive 
an inconclusive test result (Schlich-Bakker et al., 2006). 
Much of the literature neglects to discuss the psychosocial 
implications of an unclear or variant of unknown signifi-
cance result on patients participating in CGT (Voorwinden & 
Jaspers, 2016). Along these lines, future research is neces-
sary on how genetic models predict cancer risk and to deter-
mine the frequency and predictive values of less common 
variants (Hiraki et al., 2014).
Common limitations in the literature surrounding CGT 
and the related psychosocial and ethical implications involve 
small or homogeneous samples (Aspinwall et al., 2011; 
Pasacreta, 2003), lack of studies carried out in the United 
States (Bennett et al., 2012; Eijzenga et al., 2014; Ho et al., 
2010; Tuinman et al., 2008), and a lack of qualitative study 
(Aspinwall et al., 2011; Hanoch et al., 2014; Hermel et al., 
2016; Pasacreta, 2003).
Conclusion
The past 20 years have seen significant improvements in 
the field of CGT. Genetic testing is an excellent avenue 
for early identification of hereditary cancer syndromes 
and for prompt risk management and tailored treatment. 
Genetic counseling provides a personalized experience 
for patients and has been known to reduce patients’ anxi-
ety associated with a cancer diagnosis. Both qualitative 
and quantitative studies have been conducted to under-
stand the psychosocial and ethical implications of genetic 
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testing in regard to both patient care and clinical utility. 
Established literature regarding the history, role of nurses, 
and the psychosocial and ethical implications of CGT 
reveals a need for future research to fill the current gap 
that exists surrounding the psychosocial implications of 
cancer genetic panel testing, particularly with regard to 
incidental findings.
Further research in this area will be critical in defining the 
future of the nurse’s role in CGT. This research will provide 
a pathway for nursing programs to include CGT in their cur-
riculums and to set clearer expectations for nurses in this set-
ting. With improved patient outcomes in mind, the practice 
of CGT as a whole will continue to progress with further 
research as nurses, and other health care professionals are 
made more aware of how these practices affect patients 
psychosocially.
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